EA201001256A1 - Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств - Google Patents

Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств

Info

Publication number
EA201001256A1
EA201001256A1 EA201001256A EA201001256A EA201001256A1 EA 201001256 A1 EA201001256 A1 EA 201001256A1 EA 201001256 A EA201001256 A EA 201001256A EA 201001256 A EA201001256 A EA 201001256A EA 201001256 A1 EA201001256 A1 EA 201001256A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diazaspiro
antagonists
derivatives
undeckan
pulmonary diseases
Prior art date
Application number
EA201001256A
Other languages
English (en)
Other versions
EA018711B1 (ru
Inventor
Лилиан Алькараз
Эндрю Бэйли
Ричард Джеймс Булл
Тимоти Джонсон
Николас Дэвид Киндон
Эндрю Стюарт Листер
Эндрю Джеймс Роббинс
Майкл Джон Стокс
Барри Джон Теобальд
Original Assignee
Астразенека Аб
Пулмаджин Терапеутикс (Синерджи) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0802192A external-priority patent/GB0802192D0/en
Priority claimed from GB0822437A external-priority patent/GB0822437D0/en
Application filed by Астразенека Аб, Пулмаджин Терапеутикс (Синерджи) Лимитед filed Critical Астразенека Аб
Publication of EA201001256A1 publication Critical patent/EA201001256A1/ru
Publication of EA018711B1 publication Critical patent/EA018711B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)

Abstract

Производные диазаспиро[5.5]ундекана и родственные соединения в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств.
EA201001256A 2008-02-06 2009-02-04 Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств EA018711B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0802192A GB0802192D0 (en) 2008-02-06 2008-02-06 Compounds
GB0822437A GB0822437D0 (en) 2008-12-09 2008-12-09 Compounds
PCT/GB2009/000298 WO2009098448A1 (en) 2008-02-06 2009-02-04 Compounds

Publications (2)

Publication Number Publication Date
EA201001256A1 true EA201001256A1 (ru) 2011-02-28
EA018711B1 EA018711B1 (ru) 2013-10-30

Family

ID=40474981

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001256A EA018711B1 (ru) 2008-02-06 2009-02-04 Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств

Country Status (39)

Country Link
US (2) US8148373B2 (ru)
EP (1) EP2242759B1 (ru)
JP (1) JP4934223B2 (ru)
KR (1) KR101273200B1 (ru)
CN (1) CN102083839B (ru)
AR (1) AR070571A1 (ru)
AU (1) AU2009211251B2 (ru)
BR (1) BRPI0908353B8 (ru)
CA (1) CA2713322C (ru)
CL (1) CL2009000271A1 (ru)
CO (1) CO6290662A2 (ru)
CR (1) CR11623A (ru)
CU (1) CU23911B1 (ru)
CY (1) CY1113734T1 (ru)
DK (1) DK2242759T3 (ru)
DO (1) DOP2010000246A (ru)
EA (1) EA018711B1 (ru)
EC (1) ECSP10010390A (ru)
ES (1) ES2394547T3 (ru)
HK (1) HK1149258A1 (ru)
HN (1) HN2010001563A (ru)
HR (1) HRP20120968T1 (ru)
IL (1) IL207038A (ru)
ME (1) ME01532B (ru)
MX (1) MX2010008577A (ru)
MY (1) MY149731A (ru)
NI (1) NI201000138A (ru)
NZ (1) NZ586872A (ru)
PE (1) PE20091572A1 (ru)
PL (1) PL2242759T3 (ru)
PT (1) PT2242759E (ru)
RS (1) RS52557B (ru)
SA (1) SA109300094B1 (ru)
SI (1) SI2242759T1 (ru)
SV (1) SV2010003642A (ru)
TW (1) TWI453209B (ru)
UA (1) UA100400C2 (ru)
UY (1) UY31639A1 (ru)
WO (1) WO2009098448A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008359B2 (en) 2002-08-23 2021-05-18 Illumina Cambridge Limited Labelled nucleotides
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
UA100400C2 (ru) 2008-02-06 2012-12-25 Астразенека Аб Производные спироциклических амидов
JP4837800B2 (ja) 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンm3受容体アンタゴニストとしてのキヌクリジン誘導体
WO2010067102A1 (en) * 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2426121A4 (en) 2009-04-30 2012-10-31 Teijin Pharma Ltd QUARTER AMMONIUM SALT CONNECTION
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
GB0913345D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB201107985D0 (en) * 2011-05-13 2011-06-29 Astrazeneca Ab Process
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
LT2820008T (lt) 2012-03-02 2017-06-12 Genentech, Inc. Amido spirociklinio amido ir sulfonamido dariniai
JP6041643B2 (ja) * 2012-11-30 2016-12-14 関東電化工業株式会社 3,3,3−トリフルオロプロピオニル化合物の製造方法
AP2015008573A0 (en) 2012-12-18 2015-07-31 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonsit activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之烷基衍生物
TW201615642A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
MA43158B1 (fr) 2015-10-23 2020-03-31 Esteve Pharmaceuticals Sa Composés oxa-diazadispiro possédant une activité contre la douleur
MY193423A (en) 2015-11-16 2022-10-12 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
WO2018059537A1 (zh) * 2016-09-30 2018-04-05 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途
RU2722720C1 (ru) 2016-12-14 2020-06-03 Бейджинг Шоубай Фармасьютикэл Ко., Лтд. Класс бифункциональных соединений со структурой соли четвертичного аммония
CN108264456A (zh) * 2016-12-30 2018-07-10 湖北尚赛光电材料有限公司 2,8-二溴屈的合成方法及其合成中间体
MA50395A (fr) 2017-10-17 2020-08-26 Esteve Pharmaceuticals Sa Sels de (r)-9-(2,5-difluorophénéthyl)-4-éthyl-2-méthyl-1-oxa-4,9-diazaspiro [5.5]undécan-3-one
CN111349003B (zh) * 2018-12-20 2023-10-03 四川科瑞德制药股份有限公司 一种丙戊酸钠的制备方法
JPWO2021201036A1 (ru) 2020-03-31 2021-10-07
WO2023213922A1 (en) * 2022-05-04 2023-11-09 Symrise Ag PRECURSORS FOR THE CONTROLLED RELEASE OF α,β-UNSATURATED ALDEHYDES OR KETONES AND OTHER HIGH IMPACT FRAGRANCE SUBSTANCES

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707186A (en) * 1954-05-06 1955-04-26 Hoffmann La Roche Imidazolone derivatives
GB9604578D0 (en) 1996-03-04 1996-05-01 Sericol Ltd Photocurable compositions
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU6539400A (en) 1999-08-13 2001-03-13 Gore Enterprise Holdings, Inc. Fibrous polymeric material and its composites
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) * 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
ES2329133T3 (es) * 2003-05-28 2009-11-23 Theravance, Inc. Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos.
PL1751131T3 (pl) 2004-03-10 2009-04-30 Janssen Pharmaceutica Nv Arylopiperydyny lub -piperazyny podstawione 5-członowymi heterocyklilami jako inhibitory MTP
CN1934104A (zh) * 2004-03-23 2007-03-21 辉瑞大药厂 用于治疗疾病的化合物
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1852434B1 (en) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
JP2009521483A (ja) * 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2094646A1 (en) 2006-12-20 2009-09-02 AstraZeneca AB Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
UA100400C2 (ru) 2008-02-06 2012-12-25 Астразенека Аб Производные спироциклических амидов
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB0913342D0 (en) * 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801

Also Published As

Publication number Publication date
US8629271B2 (en) 2014-01-14
JP2011512331A (ja) 2011-04-21
TW200938549A (en) 2009-09-16
WO2009098448A8 (en) 2010-08-26
CR11623A (es) 2011-02-04
HK1149258A1 (en) 2011-09-30
DK2242759T3 (da) 2012-12-17
PT2242759E (pt) 2012-12-17
WO2009098448A1 (en) 2009-08-13
AR070571A1 (es) 2010-04-21
ES2394547T3 (es) 2013-02-01
BRPI0908353A2 (pt) 2015-07-28
RS52557B (en) 2013-04-30
EP2242759B1 (en) 2012-09-12
AU2009211251A1 (en) 2009-08-13
JP4934223B2 (ja) 2012-05-16
HN2010001563A (es) 2013-07-22
UA100400C2 (ru) 2012-12-25
EP2242759A1 (en) 2010-10-27
PE20091572A1 (es) 2009-11-04
CN102083839A (zh) 2011-06-01
CU23911B1 (es) 2013-07-31
CU20100159A7 (es) 2011-10-31
UY31639A1 (es) 2009-09-30
IL207038A0 (en) 2010-12-30
CA2713322C (en) 2017-01-17
KR101273200B1 (ko) 2013-06-17
KR20100121637A (ko) 2010-11-18
CN102083839B (zh) 2014-03-26
CL2009000271A1 (es) 2010-06-18
SA109300094B1 (ar) 2012-09-12
BRPI0908353B8 (pt) 2021-05-25
SV2010003642A (es) 2011-02-07
CA2713322A1 (en) 2009-08-13
HRP20120968T1 (hr) 2013-01-31
AU2009211251B2 (en) 2012-02-02
DOP2010000246A (es) 2010-11-15
IL207038A (en) 2015-10-29
EA018711B1 (ru) 2013-10-30
PL2242759T3 (pl) 2013-06-28
ECSP10010390A (es) 2010-11-30
US20090298807A1 (en) 2009-12-03
MX2010008577A (es) 2010-11-25
NZ586872A (en) 2012-03-30
US20120322788A1 (en) 2012-12-20
NI201000138A (es) 2012-09-10
CY1113734T1 (el) 2016-06-22
ME01532B (me) 2014-04-20
TWI453209B (zh) 2014-09-21
MY149731A (en) 2013-10-14
SI2242759T1 (sl) 2013-01-31
CO6290662A2 (es) 2011-06-20
US8148373B2 (en) 2012-04-03
BRPI0908353B1 (pt) 2019-11-05

Similar Documents

Publication Publication Date Title
EA201001256A1 (ru) Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
SMT201600164B (it) Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA200970303A1 (ru) Тиазолпиразолопиримидин в качестве антагониста рецептора крф1
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
NI201200072A (es) Métodos y composiciones para tratar cáncer
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
ES2721018T3 (es) N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
MA32537B1 (fr) Dérivés de pyrazolo [5,1-b] oxazole en tant qu'antagonistes de crf1
EA202091356A1 (ru) A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты